BlackRock, Inc. 13D and 13G filings for Regeneron Pharmaceuticals, Inc.:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Shares have been adjusted for stock splits.
| Reported DateTime |
Transaction Date |
Type | Company Symbol |
Filed By Symbol |
Shares Owned % Owned |
Shares Vs. Prev Report | View |
| 2024-01-25 4:59 pm Sale |
2023-12-31 | 13G | Regeneron Pharmaceuticals, Inc. REGN |
BlackRock Inc. BLK |
8,629,707 8.100% |
-537,110 (-5.86%) |
Filing |
| 2023-02-03 4:27 pm Sale |
2022-12-31 | 13G | Regeneron Pharmaceuticals, Inc. REGN |
BlackRock Inc. BLK |
9,166,817 8.600% |
-444,054 (-4.62%) |
Filing |
| 2022-02-01 5:08 pm Sale |
2021-12-31 | 13G | Regeneron Pharmaceuticals, Inc. REGN |
BlackRock Inc. BLK |
9,610,871 9.100% |
-165,315 (-1.69%) |
Filing |
| 2021-02-01 08:23 am Purchase |
2020-12-31 | 13G | Regeneron Pharmaceuticals, Inc. REGN |
BlackRock Inc. BLK |
9,776,186 9.300% |
3,637,338 (+59.25%) |
Filing |